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Abstract
Enterotoxigenic Escherichia coli (ETEC) are a common cause of diarrheal illness in young
children and travelers. There is yet no licensed broadly protective vaccine against ETEC.
One promising vaccine development strategy is to target strains expressing the heat-stable
toxin (ST), particularly the human ST (STh), since infections with these strains are among
the leading causes of diarrhea in children in low-and-middle income countries. A human
challenge model based on an STh-only ETEC strain will be useful to evaluate the protective
efficacy of new ST-based vaccine candidates. To develop this model, we experimentally
infected 21 healthy adult volunteers with the epidemiologically relevant STh-only ETEC
strain TW10722, identified a suitable dose, assessed safety, and characterized clinical out-
comes and immune responses caused by the infection. Doses of 1×1010 colony-forming
units (CFU) of TW10722 gave a suitable attack risk of 67% for moderate or severe diarrhea
and an overall diarrhea attack risk of 78%. Non-diarrheal symptoms were mostly mild or
moderate, and there were no serious adverse events. During the first month after ingesting
the challenge strain, we measured significant increases in both activated CD4+ T cells and
levels of serum IgG and IgA antibodies targeting coli surface antigen 5 (CS5) and 6 (CS6),
as well as the E. coli mucinase YghJ. The CS5-specific CD4+ T cell and antibody responses
were still significantly elevated one year after experimental infection. In conclusion, we have







Citation: Sakkestad ST, Steinsland H, Skrede S,
Lillebø K, Skutlaberg DH, Guttormsen AB, et al.
(2019) A new human challenge model for testing
heat-stable toxin-based vaccine candidates for
enterotoxigenic Escherichia coli diarrhea – dose
optimization, clinical outcomes, and CD4+ T cell
responses. PLoS Negl Trop Dis 13(10): e0007823.
https://doi.org/10.1371/journal.pntd.0007823
Editor: Alfredo G. Torres, University of Texas
Medical Branch, UNITED STATES
Received: June 3, 2019
Accepted: October 2, 2019
Published: October 30, 2019
Copyright: © 2019 Sakkestad et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work was partly supported by the
Research Council of Norway through the Global
Health and Vaccination Programme (GLOBVAC)
(https://www.forskningsradet.no/en/), project
number 234364. The project has received funding
from the European Union’s Seventh Framework
developed a safe STh-only ETEC-based human challenge model which can be efficiently
used in Phase 2B trials to evaluate the protective efficacy of new ST-based vaccine
candidates.
Trial registration
ClinicalTrials.gov ClinicalTrials.gov, Project ID: NCT02870751
Author summary
Enterotoxigenic Escherichia coli (ETEC) is a common cause of diarrheal illness in young
children living in low- and middle-income countries and in travelers to these countries.
Several ETEC vaccine candidates are currently being developed, but so far, no broadly
protective vaccines have been licensed. Since most moderate and severe ETEC diarrheal
episodes are caused by strains that express the heat-stable enterotoxin (ST), ST represents
a promising vaccine target. Here we present a human challenge model that can be used to
estimate the protective efficacy of ST-based vaccine candidates in clinical vaccine trials.
The model is based on the epidemiologically relevant ST-only ETEC strain TW10722,
which we show is safe to ingest by volunteers and readily induce diarrhea.
Introduction
Enterotoxigenic Escherichia coli (ETEC) are among the most important causes of diarrhea in
low-and-middle income countries (LMICs) and of travelers’ diarrhea [1, 2]. ETEC are respon-
sible for some 75 million diarrheal episodes and an estimated 50,000 deaths annually [1],
mostly in children less than 5 years of age. This is an age where enteric infections may also
cause severe sequelae such as malnutrition and impaired cognitive development [3, 4]. There
is currently no licensed broadly protective vaccine against ETEC, although several candidates
have reached different stages of pre-clinical and clinical testing [5], with one candidate cur-
rently in phase I and II vaccine trials [6]. Human ETEC secrete one or two types of enterotox-
ins called the heat-stable toxin (ST) and the heat-labile toxin (LT), both of which can induce
diarrhea by binding to receptors in the small intestinal epithelium and trigger secretion of salts
and fluid into the gut lumen [7]. In contrast to the large and immunogenic LT, ST is small and
non-immunogenic and is found in two close to identical variants called porcine ST (STp, a.k.a.
STaI or pSTa) and human ST (STh, a.k.a. STaII or hSTa) [8]. While strains producing STh
only appear to cause diarrhea in humans, STp-producing strains are also often associated with
diarrheal illnesses in newborn piglets and calves [9].
ETEC that express ST (with or without LT) is an important cause of moderate-to-severe
diarrhea among young LMIC children. Furthermore, STh-producing strains are epidemiologi-
cally more important than STp-producing strains [10, 11]. Development of an efficient vaccine
targeting diarrhea-inducing ST-ETEC strains is of great global health interest, and recently,
important obstacles to produce safe and immunogenic ST-based vaccines have been overcome
[12–14], partly by coupling otherwise non-immunogenic ST molecules to larger immunogens
[8]. Although no ST-based vaccine candidates have reached clinical evaluation, there is now a
need to prepare for these trials by developing a human challenge model that can be used to test
them in Phase 2B (vaccine challenge) trials. Such a human challenge model should be based on
a wild-type ETEC strain that produces STh, but not LT, since diarrhea induced by the latter
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would obscure protection conferred by immunity to ST, which would lead to an underestima-
tion of vaccine-induced protection. Another important application of a human STh-only
ETEC challenge model would be to evaluate the effect of LT-based adjuvants, such as the dou-
ble mutant LT (dmLT) [15]. Specifically, if an LT-expressing challenge strain was used to test
vaccine candidates using LT-based adjuvants, antibodies elicited by this adjuvant would poten-
tially contribute to the overall protection by targeting native LT, making it more difficult to
evaluate the effect of the adjuvant on the induction of protective immunity separately from the
vaccine antigen.
Identifying a suitable wild-type ETEC strain and the optimal dose represents pivotal steps
in developing a human challenge model. The strain should be safe to ingest and the doses
should be high enough to ensure that most immunologically naïve volunteers develop diar-
rhea, while not so high as to risk overwhelming an otherwise protective vaccine-induced
immunity [16]. In future vaccine challenge trials with ST-based vaccine candidates, volunteers
will first receive either the vaccine or placebo and subsequently be experimentally infected
with a suitable ST-only ETEC strain. If the ST-based vaccine candidate is efficacious, the vacci-
nated volunteers should be healthier after being challenged with the ETEC strain than the vol-
unteers who received the placebo vaccination. Until now, two ST-only strains have been tested
in volunteer experimental infection studies, including the STp-only 214–4 strain [17] and the
STh-only TW11681 strain [18]. Neither of them are optimal because infections with STp-pro-
ducing strains are not usually associated with moderate-to-severe diarrhea among LMIC chil-
dren [10, 11], and experimental infection with the STh strain only gave mild diarrhea and a
low diarrhea attack risk in volunteers [18].
The main goal of the present study was to evaluate whether the epidemiologically relevant
STh-only ETEC strain TW10722 would be safe and useful for testing ST-based ETEC vaccine
candidates in human challenge trials. We here assess safety, identify the optimal dose, and
report on clinical outcomes and immune responses following experimental infection with
strain TW10722.
Materials and methods
Volunteers and study setting
We recruited 21 healthy students from the University of Bergen (UiB), Bergen, Norway, who
had no history of travel to LMICs during the previous 12 months. The volunteers were
recruited on the UiB campus through oral and written information about the project, and
those interested were individually given in-depth oral and written information. Before obtain-
ing a written informed consent for participation in the study, the volunteers were given a writ-
ten questionnaire to make sure they understood the rationale and requirements of the study,
including procedures to be undertaken and the potential risks. A description of the inclusion
and exclusion criteria, as well as the enrollment process, has been described in detail earlier
[18]. The study was conducted at the Infectious Diseases (ID) ward at the Division for Infec-
tious Diseases at Haukeland University Hospital (HUH) in Bergen between 2014 and 2018,
with 9 volunteers recruited between September and November 2014 and 12 between Septem-
ber 2017 and March 2018. We included volunteers in groups of three, and each triplet shared a
cohort isolation room for up to 10 days after dose ingestion.
Strain description
ETEC strain TW10722, with serotype O115:H5, was isolated in Guinea-Bissau in 1997 from a
15-month old child suffering from acute diarrhea [11] and kept frozen at -70˚C afterwards. It
is sensitive to ciprofloxacin, chloramphenicol, and gentamycin, and expresses STh, but not LT
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or STp. It also expresses the two ETEC colonization factors coli surface antigen 5 (CS5) and 6
(CS6), and is EtpA negative [19]. Strain TW10722 has been shown to produce ST in in-vitro
assays (Jacob P. Bitoun, personal communication). The strain’s genome has been sequenced
(GenBank BioProject no.: PRJNA190209), and results from phylogenetic analyses indicate that
it is a good representative of an ETEC family that contributes substantially to childhood diar-
rhea in LMICs (ETEC5 [20]; L5 [21]).
Dose preparation
A working cell bank of TW10722 was prepared by the Inoculum Preparation Laboratory at the
Center for Vaccine Development and Global Health, University of Maryland School of Medi-
cine, Baltimore, MD, and shipped on dry ice to the study site in Bergen, Norway. The doses
given to the volunteers were prepared from these working cell banks similarly to what has
been described earlier [18]. Briefly, cells from a vial of frozen working cell bank culture were
streaked onto three agar plates that had been prepared with BD Difco Select APS Luria-Bertani
animal product-free broth (APF-LB; Becton Dickinson, Franklin Lakes, NJ). Following over-
night incubation at 37˚C, two colonies from each of the three plates were picked and sus-
pended together in 0.7 mL sterile phosphate buffered saline (PBS). We spread 100 μL of this
suspension onto six (for preparing 1×1010 colony forming units (CFU) doses) or three (for
preparing smaller doses) approximately 10 mm thick APF-LB agar plates prepared in 90 mm
petri dishes and incubated them at 37˚C for approximately 19 hours, until 2 hours before the
volunteers were to ingest the doses. Cells were harvested by scraping from three plates and
pooled in a 15 mL Falcon tube containing 10 mL cold PBS. For 1×1010 CFU doses, we pre-
pared two tubes (from 6 plates). After resuspending the cells by vortexing, we centrifuged the
tubes at 2,000 × g for 5 min at 4˚C, poured off the supernatant, and added 10 mL cold PBS.
This washing procedure was repeated twice before cell concentration of the resulting stock
solution was estimated by measuring the optical cell density at 600 nm (OD600) of diluted
stock solution in 10 mm path length cuvettes. We aimed for OD600 measurements between
0.2 and 0.9 and used a conversion factor of 0.9×109 CFU/mL/OD600 to obtain the estimated
cell concentration. The stock solution was subsequently diluted in PBS so that each dose was
contained in 2 mL PBS suspension. The actual dose given was checked by preparing 10-fold
dilution series of the suspension and plating three appropriate dilutions onto LB agar plates in
triplicates. This was done both before the doses left the laboratory and after the remaining
solutions were returned from dose ingestion at the clinical ward. The 18 plates were incubated
overnight at 37˚C and the dose confirmed by colony counting. In this study, we prepared sepa-
rate doses for each group of 3 volunteers. The actual doses given to the volunteers were
1.01×106 CFU (for the 1×106 CFU dose group), 1.00×107 CFU (for the 1×107 CFU dose
group), 0.97×108 CFU (for the 1×108 CFU dose group), 1.46×109 CFU (for the 1×109 CFU
dose group), and 0.77×1010, 0.86×1010, and 0.87×1010 CFU (for the three 1×1010 CFU dose
groups).
Experimental infection and follow up
The volunteers ingested TW10722 in groups of three at a time, starting at a low dose of 1×106
CFU for the first group, as TW10722 had previously not been tested in humans. The dose
would, if none or only one volunteer developed diarrhea, be increased 10-fold for the next
group, provided the senior study physician (KH) considered it safe to do so. Before dose inges-
tion, the volunteers fasted from midnight until the dose was given at around 11:00 am the fol-
lowing day. The volunteers first drank 120 mL 1.33% bicarbonate buffer while 30 ml 1.33%
bicarbonate buffer was added to the 2 ml dose. After one minute, the volunteers ingested this
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suspension, and they could eat and drink normally 1 hour afterwards. The infection was
cleared by administering 500 mg ciprofloxacin two times daily for three days starting 5 days
after the dose was ingested. Antibiotic treatment was started earlier if a volunteer experienced
severe diarrhea or moderate diarrhea lasting for�24 hours, if a volunteer had mild diarrhea
accompanied by two or more non-diarrheal symptoms (fever, vomiting, abdominal pain or
cramping, headache, myalgias or nausea) for two days, or if it was considered necessary for
other reasons by the senior study physician. Stool specimens (rectal swabs, if stool specimens
were unavailable) were collected and screened for the presence of ETEC at least once each day.
The specimens were plated on lactose agar and incubated overnight in ambient air at 35˚C. A
representative selection of E. coli-like colonies from the plate were pooled and the presence of
the challenge strain was determined by detecting the ST gene using real-time PCR as described
earlier [22]. The volunteers were kept at the ID ward under the hospital’s enteric precaution
guidelines until antibiotic treatment had started and three consecutive stool specimens were
negative for ETEC. For all volunteers, we collected blood by venipuncture immediately before
dose ingestion as well as 10 and 28 days after. For the 9 volunteers recruited first to the study,
we obtained long-term follow-up samples at 2 years after dose ingestion, while for the 12 vol-
unteers recruited last we obtained samples after 6 months and 1 year.
Clinical assessment
We recorded the volunteers’ vital signs and assessed their physical health and wellbeing imme-
diately before dose ingestion and at least three times daily thereafter. We also performed a daily
review of the symptoms noted by each volunteer on a self-report form. Here, the volunteers reg-
istered any nausea, abdominal pain or cramping, flatulence, bloating, vomiting, constipation,
decreased appetite, headache, malaise, fever, chills, myalgias, and lightheadedness, and graded
them as being mild (relieved by using relevant treatment and/or resulting in no disruption of
normal daily activities), moderate (only partially relieved by relevant treatment and resulting in
some disruption of daily activities), or severe (not relieved by relevant treatment and resulting
in disruption of daily activity) [23]. Volunteers who had an axillary temperature reading of
�38.0˚C (measured by using a Bosotherm Basic thermometer [Bosch + Sohn GmbH und Co.,
Jungingen, Germany]) were classified as having fever. All stools produced by the volunteers
were collected and weighed in single-use plastic toilet receptables. As previously described, the
stools were graded based on whether it was firm and formed (Grade 1), soft and formed (Grade
2), viscous opaque liquid or semiliquid (Grade 3), opaque liquid (Grade 4) or clear or translu-
cent liquid (Grade 5). An episode of diarrhea was defined as the passing of 1 loose/liquid stool
(Grade�3) totalling�300 g, or�2 loose/liquid stools totalling�200 g during any 48-hour
period within 120 hours after the volunteer had ingested the dose. The severity of each diarrheal
episode was further graded as being mild (1–3 loose stools totalling 200–400 g/24 h), moderate
(4–5 loose stools totalling 401–800 g/24 h) or severe (�6 loose stools totalling�801 g/24 h)
[23]. Based on a combined scoring of symptoms, signs and diarrheal severity, we estimated the
disease severity score of each episode, ranging from 0 (least severe) to 8 (most severe) [24].
Immunoassay antigen preparation
We used PCR to amplify the genes that encode the structural subunits of two ETEC coloniza-
tion factors CS5 (csfA) and CS6 (cssA) produced by TW10722, as well as the gene for its E. coli
mucinase YghJ (yghJ). YghJ is a 170 kDa protein that pathogenic E. coli commonly secrete to
break down the protective mucus barrier on the small intestinal epithelium [25]. CS5 and CS6
help anchor ETEC to the intestinal epithelial cells. The structural part of CS5 is made up of
multiple repeats of the major subunit CsfA (19 kDa), and the structural part of CS6 is made up
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of two subunits of similar structure, CssA (15 kDa) and CssB (16 kDa) [26]. The UniProtKB
reference accession numbers for the proteins used in immunological assays in the present
study are P33781 (YghJ), P0CK95 (CsfA) and P53508 (CssA). The relevant PCR fragments
were ligated into pET-30 (for CsfA and YghJ) and pET-32 (for CssA) expression vectors and
transformed into ClearColi BL21(DE3) (Lucigen Corp., Middleton, WI), which produces
genetically altered LPS that do not trigger unwanted endotoxic responses in T cell assays. To
express the proteins, cells were cultured for 50 hours at room temperature in the presence of
isopropyl β-D-1-thiogalactopyranoside. Cleared lysates and inclusion bodies were generated
by enzymatic lysis (lysozyme) and centrifugation. CsfA and CssA were purified from inclusion
bodies, while YghJ was purified from cleared lysates. Proteins in inclusion bodies were dena-
tured by using urea and subsequently renatured by diluting the urea concentration. All pro-
teins were subsequently purified by using HisPur Ni-NTA Resin (Thermo Fisher Scientific,
Waltham, MA) according to manufacturer’s instruction. The eluted proteins were dialyzed
over night against PBS across a 10 kDa molecular weight cut-off membrane, the protein con-
centrations were determined by using the Pierce Micro BCA Protein Assay Kit (Thermo Fisher
Scientific), and we assessed the quality of the purified proteins by using SDS-PAGE analyses.
In those analyses, we confirmed the presence of proteins that had the predicted sizes of CsfA,
CssA, and YghJ, and that, by analyzing band signal intensities, these proteins represented
>90% of the total peptide content in the solution. We found little or no sign of protein degra-
dation. The proteins were stored in low protein binding tubes at -20˚C until use. In the text,
we use “CS5” and “CS6A” to refer to CsfA and CssA, respectively.
The CS6 fusion protein (CssAdsB-CssBdsA) consists of the CssA subunit complemented by
the donor strand of the CssB subunit (dsB) and the CssB subunit complemented by the donor
strand of the CssA subunit (dsA) (S1 Fig). We consider the CS6 fusion protein to be more rep-
resentative of the CS6 antigens produced by the strain than the CS6A preparation, but we have
used CS6A in the T cell assays because the fusion protein was not available during the initial
part of the study. The construction of the pET-CssAdsB-CssBdsA plasmid expressing this
afimbrial ETEC surface antigen has been previously described [27]. pET-CssAdsB-CssBdsA
was transformed into Endotoxin-Free ClearColi BL21 (DE3) cells (Invitrogen, USA). E. coli
transformants were cultivated in Luria-Bertani (LB)-medium containing 100 μg/ml of ampicil-
lin at 37˚C. Cells were grown to an OD of 1.4 at 600 nm and induced with 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) as a final concentration for protein expression. The culture
was further grown for 4 hours and expressed proteins were extracted by osmotic shock [28].
The periplasmic fraction (60 ml) was dialyzed twice against 1 liter of 20 mM Tris-HCl, pH 7.8
buffer before purification. The protein was purified by an anion exchange chromatography
using a Source Q column in 20 mM Tris-HCl buffer, pH 7.8 at 4˚C. A 0–300 mM gradient of
NaCl was used to elute the protein. Fractions containing the target protein were pooled and
dialyzed overnight in 20 mM Tris-HCl, pH 7.5 buffer. Further purification was performed by
another anion exchange column in 20 mM Tris-HCl, pH 7.5 using a Mono-Q column (GE
Healthcare) with a 0–200 mM gradient of NaCl at 4˚C. Fractions containing CssAdsB-
CssBdsA were pooled and dialyzed in PBS-buffer for later use. In the text, we use “CS6AB” to
refer to the CssAdsB-CssBdsA fusion protein.
T cell assay
To investigate antigen-specific CD4+ T cell responses to the experimental infection, we incu-
bated 500 μL sodium-heparinized whole blood with 10 μg purified CS5, CS6A or YghJ for 2
days, and then counted CD25- and CD134 (OX40)-expressing CD4+ T cells using flow cytom-
etry [29, 30]. The T cell assay methodology has previously been described in detail [18]. Briefly,
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for all volunteers and blood sampling time points, we cultured cells in sodium-heparinized
whole blood in X-VIVO 15 Serum-free Hematopoietic Cell Medium with Gentamicin and
Phenol Red (Lonza Ltd, Basel, Switzerland) containing 10 μg purified protein/mL. Staphylo-
coccal Enterotoxin B (SEB; 0.1 μg/mL) (Sigma-Aldrich, St. Louis, Missouri) was used as a posi-
tive control, and cells cultured in medium only were used as a negative control. The reagents
(minus the blood cells) were mixed and frozen at -80˚C in 500 μl aliquots in 24-well cell culture
plates (Corning Incorporated, Corning, NY) and thawed before use. Specimens from the same
volunteer were analysed by using reagents from the same frozen batch, except that new mixes
containing new preparations of antigens were made for analysing the 2 year follow-up samples.
For each analyses, we added 500 μl blood to each reagent mix and, after incubating for 42–48
hours at 37˚C and 5% CO2, we added a hypotonic buffer to lyse erythrocytes, and subsequently
stained the remaining cells by adding fluorescently-labelled antibodies targeting CD3, CD4,
CD8, CD14, CD25 and CD134 (S1 Table), as well as 7-AAD Cell Viability Solution (BioLe-
gend, San Diego, CA). Live singlet CD4+ T lymphocytes were identified by using an LSR For-
tessa flow cytometer (BD Biosciences, San Jose, CA). We collected a minimum of 50,000
events in the lymphocyte gate (S2 Fig). We used FlowJo, version 10.5.3 (FlowJo LLC, Ashland,
OR) to estimate the percentage of cells co-expressing CD25 and CD134 as a measure of acti-
vated antigen-specific CD4+ T cells [30] (S2 Fig).
Antibody assay
To explore the serum antibody responses to the experimental infection, we performed a multi-
plex bead-based flow cytometric immunoassay to measure antibody levels against CS5,
CS6AB, and YghJ. The methodology has previously been described in detail [18]. Briefly, CS5,
CS6AB, YghJ, and the negative control glutathione S-transferase (GST) were covalently cou-
pled to 5 μm Ø Cyto-Plex carboxylated beads (Thermo Fisher Scientific) of different fluores-
cence intensities. The beads were subsequently incubated with 1:50-diluted serum before
incubation with fluorescently-labeled secondary antibodies that recognize human IgA (Alexa
Fluor 488-AffiniPure Goat Anti-Human Serum IgA [Jackson ImmunoResearch] and human
IgG (Goat anti-human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 555
[Invitrogen, Waltham, Massachusetts]). Serum collected from all 21 volunteers on day 0, 10
and 28, as well 6 months (n = 12) and 2 years (n = 9) following dose-ingestion were included
in the analyses (1-year samples were not available at the time we performed this assay). Fluo-
rescence levels of the labeled beads were measured on an LSR Fortessa flow cytometer. As a
measure of protein-specific serum antibody levels, we used FlowJo to calculate the median
fluorescence intensity (MFI) of the beads for each protein and subtracted the corresponding
MFI value of the GST-labeled negative control beads.
Statistical analyses
We tested for differences in antigen-specific CD4+ T cell and antibody levels between blood
specimens collected at different time points using the Wilcoxon matched-pairs signed rank
test in GraphPad Prism (GraphPad Software Inc., La Jolla, CA). To estimate the association
between CD4+ T cell or antibody levels, dose, and the presence of diarrhea, we performed
multiple linear regression analyses using SPSS (IBM SPSS Statistics for Windows Version 25.0,
Chicago, Illinois). In these regression models, we included the target dose (CFU) and
experiencing a diarrheal episode (yes/no) as independent variables, and the fold-change from
day 0 to day 10 or 28 in antibody or CD4+ T cell levels as the dependent variable. Fold changes
represent the ratio between the measured (i.e. day 10 and 28) and the baseline (i.e. day 0) val-
ues. We used linear regression to examine the association between anti-CS5, -CS6AB, and
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-YghJ antibody levels and the corresponding antigen-specific CD4+ T cell responses. For each
tested antigen, we included the log10 transformed absolute difference in CD4+ T cell levels
from day 0 to day 10 as the independent variable, and the log10 transformed absolute differ-
ence in serum IgG or IgA peak levels (from day 0 to day 28 [CS5] or from day 0 to day 10 [for
CS6AB and YghJ]), was included as the dependent variable. Absolute differences were calcu-
lated by subtracting the baseline (i.e. day 0) from the measured (i.e. day 10 and 28) values. The
significance threshold was set at p <0.05.
Ethics statement
All volunteers gave an informed written consent before being included in the study. The study
is approved by the Regional Committee for Medical and Health Research Ethics, Health
Region West (Project ID: 2014–826), and registered in ClinicalTrials.gov (Project ID:
NCT02870751). The study was assessed by an independent safety monitor before, during and
after enrollment of volunteers to ensure adherence to Good Clinical Practice (GCP) standards.
Results
Volunteer characteristics
A total of 21 healthy adult volunteers, of which 18 were women, were enrolled for experimental
infection with strain TW10722 (Fig 1). They were 19 to 29 years old and had a body mass
index (BMI) varying from 19.3 to 27.4 kg/m2. Among the 12 volunteers from which we
obtained 1-year samples, 2 had been traveling in ETEC endemic countries since the previous
follow-up, while 8 of the remaining 9 volunteers from whom we obtained 2-year samples had
traveled to such countries.
Dose optimization and clinical outcomes
For the 21 volunteers included in this study, we administered the following doses: 1×106
(n = 3), 1×107 (n = 3), 1×108 (n = 3), 1×109 (n = 3) and 1×1010 (n = 9) CFU. Up to and includ-
ing doses of 1×109 CFU, at most one in three volunteers developed diarrhea (Table 1). At
1×1010 CFU doses, the volunteers more consistently developed diarrhea, with 2 out of 3 volun-
teers developing diarrhea in the first enrolled triplet, and a total 7 out of 9 volunteers (78%,
95% confidence interval [CI]: 44% to 95%) falling ill, 6 of whom experienced moderate or
severe diarrhea. Among the volunteers who developed diarrhea, each 10-fold increase in dose
was associated with 11.6 hours (95% CI: 8.3 to 14.9) shorter incubation period. Three volun-
teers, all of whom experienced severe diarrhea, received early antibiotic treatment. The volun-
teers who received doses ranging from 1×106 to 1×109 CFU had a similar age distribution and
similar BMI measurements compared to those given 1×1010 CFU doses.
For all volunteers, nausea, malaise and headache were frequently occurring symptoms, and
they were observed more often at higher doses (Table 2). Apart from three episodes of moder-
ate or severe lightheadedness, however, the symptoms were all reported to be mild or moder-
ate, which contributed to relatively low disease severity scores (Table 3). Two volunteers
developed mild fever (both 1×108 CFU doses), and two experienced vomiting (both 1×1010
CFU). There were no serious adverse events, and none of the volunteers needed administra-
tion of oral rehydration salts solution or intravenous fluid.
CD4+ T cell responses
Following incubation of peripheral blood with CS5, we found a mean 5.5-fold increase in the
percentage of activated antigen-specific CD4+ T cells, from 0.47% on day 0 to 2.58% on day 10
ST-only ETEC human challenge model
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(p< 0.0001) (Fig 2). Although the levels were slightly reduced after this, they remained
markedly elevated both 28 days (5.1-fold, p< 0.0001) and 6 months after dose ingestion, and
even in the 1- and 2-year follow-up samples. In total, there were 20 volunteers (95%) who
responded with a� 2.0-fold and 16 volunteers (76%) with a� 4.0-fold increase in the percent-
age of activated CD4+ T cells after CS5 stimulation.
Following incubation of peripheral blood with CS6A and YghJ we also observed increases
in the percentage of activated antigen-specific CD4+ T cells, but the responses were generally
weaker and less long-lived than those seen for CS5; a maximum 1.9-fold increase for CS6A
(p< 0.001) from day 0 to day 10 and a maximum 2.0-fold increase (p< 0.0001) for YghJ from
day 0 to day 28. In total there were 10 volunteers (83%) who responded with a� 2.0-fold
increase in the percentage of CS6A-specific CD4+ T cells, and 16 volunteers who responded
with the same fold increase in the percentage of YghJ-specific CD4+ T cells. Purified CS6A
was not available in the initial part of the study, which is why this antigen was only tested in
samples from the 12 last recruited volunteers (Fig 2).
Averaged across all volunteers and sampling timepoints, whole blood incubation with
medium only (negative control) activated a mean 0.03% of CD4+ T cells, while incubation
with Staphylococcal Enterotoxin B (positive control) activated a mean of 14.5%.
Serum antibody responses
Levels of serum antibodies targeting CS5 increased substantially from day 0 to day 28, with a
mean 10.5-fold MFI increase in anti-CS5 IgG (p< 0.0001) and a mean 5.2-fold MFI increase
in anti-CS5 IgA (p< 0.0001) (Fig 3). Six months after the experimental infection, the antibody
levels remained very high for IgG, and somewhat less, yet still significantly so, for IgA. In total,
there were 17 volunteers (81%) who developed a� 4.0-fold increase in anti-CS5 IgA levels,
and correspondingly 12 volunteers (57%) with the same fold increase in anti-CS5 IgG levels.
Elevated antibody levels could be detected even 2 years after dose ingestion, with a mean
6.0-fold increase from baseline in IgG (p = 0.008) and a 4.1-fold increase from baseline in IgA
(p = 0.004) compared to the day 0 levels.
Fig 1. Flow diagram. CONSORT flow diagram as applies for human challenge studies. In total 22 adult volunteers were assessed for eligibility, and
1 volunteer did not meet the inclusion criteria, resulting in a total of 21 volunteers allocated to experimental infection with different doses of ETEC:
1×106 (n = 3), 1×107 (n = 3), 1×108 (n = 3), 1×109 (n = 3) and 1×1010 (n = 9) CFU. Clinical data were analyzed for all volunteers, as well as the
immunological data on day 10 and day 28 after experimental infection. There were none lost to follow-up, however, immunological data from 6
months, 1 year and 2 years after experimental infection were obtained from subgroups of the study population due to limited availability of
personnel to perform the analyses.
https://doi.org/10.1371/journal.pntd.0007823.g001





























1 × 106 3 0 0% NA� NA� NA� NA� NA� NA�
1 × 107 3 1 33% Mild 58 286 286 0 1
1 × 108 3 1 33% Severe 44 1773 2754 42 11
1 × 109 3 1 33% Severe 46 543 543 13 7
1 × 1010 9 7 78% Moderate 23 (18–26) 492 (389–711) 496 (389–711) 14 (0–66) 4 (1–8)
� NA: Not applicable.
https://doi.org/10.1371/journal.pntd.0007823.t001
ST-only ETEC human challenge model
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007823 October 30, 2019 10 / 19
Correspondingly, we measured significant increases in serum antibody levels targeting
YghJ (Fig 3). These developed faster than the CS5 responses, but were generally lower and
more short-lived, and markedly more consistent for IgA levels (17 volunteers [81%]
with� 2.0-fold increase) compared to IgG levels (3 volunteers [14%] with� 2.0-fold increase).
A modest mean increase of 1.3-fold in anti-YghJ IgG was observed from day 0 to day 10
(p< 0.0001), and the levels were stably elevated to day 28 before dropping to baseline levels 6
months after dose ingestion. An equally rapid, but stronger response was seen for anti-YghJ
IgA, with a 3.7-fold increase from day 0 to day 10 (p< 0.0001) before levels gradually declined
towards 28 days and 6 months after dose ingestion.
The anti-CS6AB antibody increases were generally weaker than for CS5 and YghJ, and the
responses seemed to be more heterogeneous, with some volunteers having peak anti-CS6AB
antibody levels on day 10, while others had peak levels on day 28, or appeared to remain largely
unresponsive throughout the follow-up period. In total, there were 2 volunteers (10%) who
developed a� 2.0-fold increase in anti-CS6AB IgG, and correspondingly 5 volunteers (24%)
with the same fold increase in anti-CS6AB IgA levels. Overall, we observed a mean 1.5-fold
increase in anti-CS6AB IgG (p = 0.006) and a 1.3-fold increase in anti-CS6AB IgA (p = 0.014)
from day 0 to day 10.








Nausea 4 (33) 6 (67) 10 (48)
Abdominal pain 5 (42) 6 (67) 11 (52)
Abdominal cramping 2 (17) 5 (56) 7 (33)
Excessive flatus 4 (33) 7 (78) 11 (52)
Decreased appetite 1 (8) 2 (22) 3 (14)
Bloating 4 (33) 7 (78) 11 (52)
Vomiting 0 (0) 2 (22) 2 (10)
Constipation 0 (0) 1 (11) 1 (5)
Headache 4 (33) 5 (56) 9 (43)
Malaise 3 (33) 6 (67) 10 (48)
Fever 2 (17) 0 (0) 2 (10)
Chills 1 (8) 0 (0) 1 (5)
Generalized myalgias 1 (8) 0 (0) 1 (5)
Lightheadedness 3 (25) 2 (22) 5 (24)
Hypovolemia 0 (0) 0 (0) 0 (0)
The table displays the number of volunteers experiencing each symptom or sign (percentages in parentheses).
https://doi.org/10.1371/journal.pntd.0007823.t002
Table 3. Mean disease severity scores among 21 volunteers experimentally infected with ETEC strain TW10722.
Dose (CFU) N Mean sub-score Mean disease severity score (0–8)
Objective signs (0–2) Subjective symptoms (0–2) Diarrhea score (0–4)
1 × 106 3 0.0 0.3 0.0 0.3
1 × 107 3 0.0 1.0 0.3 1.3
1 × 108 3 1.3 1.0 1.3 3.7
1 × 109 3 0.0 0.7 0.7 1.3
1 × 1010 9 0.2 1.0 1.6 2.8
https://doi.org/10.1371/journal.pntd.0007823.t003
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Associations between clinical symptoms and immune responses
Results from multiple linear regression analysis showed that volunteers developing diarrhea
(n = 10) tended to have higher increases in antigen-specific antibody and CD4+ T cell levels
compared to volunteers who did not develop diarrhea (n = 11). However, only the increase
from day 0 to day 28 in anti-CS5 IgA (p = 0.036), as well as the increase from day 0 to day 10
in YghJ-specific CD4+ T cells (p = 0.033) were significantly associated with developing diar-
rhea. There was no clear association between inoculation dose and CS5-, CS6-, or YghJ-spe-
cific antibody or activated CD4+ T cell levels.
Associations between antibody and CD4+ T cell responses
Linear regression analysis using log10 transformed values showed that increases in CS5- and
CS6AB-specific antibody levels were associated with increases in the corresponding antigen-
Fig 2. Antigen-specific CD4+ T cell responses after infection with STh-only ETEC strain TW10722. The graph displays the mean percentage of CD4+ T
cells that co-express CS25 and CD134 for each sampling timepoint and virulence factor after incubating whole blood with ETEC proteins CS6A, CS5 and
YghJ. Grey circles represent volunteers in the 1×106 to 1×109 CFU dose groups, red circles represent volunteers in the 1×1010 CFU dose group. Error bars
represent the 95% confidence intervals. Due to limited availibility of purified CS6 antigen in the initial parts of the study, CS6-specific CD4+ T cell responses
were only measured for a subgroup of the volunteers (n = 12). Also, due to the stepwise inclusion of volunteers to the study, the long-term follow-up
timepoints of each volunteer varied according to time of enrollment, with the first subgroup of volunteers (n = 9) having their follow-up at 2 years, while the
last subgroup of volunteers (n = 12) had their follow-up at 6 months and 1 year after experimental infection. Abbreviations: d0: day 0, d10: day 10, d28: day 28,
m6: 6 months, y1: 1 year, y2: 2 years, N: Number of volunteers, Stim: Antigen used for stimulation. a Antigen preparation differed from other timepoints.
https://doi.org/10.1371/journal.pntd.0007823.g002
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specific CD4+ T cell responses. The association was significant for anti-CS5 IgA (p = 0.023)
and anti-CS6AB IgA (p = 0.048), and approaching significance for anti-CS5 IgG (p = 0.051)
and anti-CS6AB IgG (p = 0.068). No significant association was found between the humoral
and cellular YghJ-specific responses.
Fig 3. Antigen-specific serum IgG and IgA responses after infection with STh-only ETEC strain TW10722. The graphs display the median fluorescence
intensity (MFI) value of CS5-, CS6AB-, and YghJ-specific IgG and IgA at each sampling time point for each volunteer. Grey circles represent volunteers in the
1×106 to 1×109 CFU dose groups, red circles represent volunteers in the 1×1010 CFU dose group. Error bars represent the 95% confidence intervals. Number
of volunteers indicated in parentheses. Abbreviations: d0: day 0, d10: day 10, d28: day 28, m6: 6 months, y2: 2 years.
https://doi.org/10.1371/journal.pntd.0007823.g003
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Discussion
With the aim to develop a human challenge model that can be used to estimate the protective
efficacy of ST-based vaccine candidates in Phase 2B trials, we set out to identify a suitable epi-
demiologically relevant ST-only ETEC strain that would be safe to administer to volunteers
and induce diarrhea in around 70% of them. We here demonstrate that a dose of 1×1010 CFU
yielded a suitable overall diarrhea attack risk of 78% (95% CI: 40% to 97%) and a moderate or
severe diarrhea attack risk of 67% (95% CI: 30% to 93%). Although experimentally infecting
more volunteers with this dose would have improved the precision of the attack risk estimates,
we believe they are good approximations of the true attack risks for this model. Nevertheless,
their precision will improve as actual vaccine challenge studies generate data.
We also demonstrated that it is safe for healthy human volunteers to ingest ETEC strain
TW10722 at 1×1010 CFU. The non-diarrheal symptoms associated with this dose were mostly
mild or moderate, and none of the volunteers experienced any severe adverse events or needed
oral rehydration salts or intravenous solutions. Finally, most volunteers elicited strong specific
antibody and CD4+ T cell responses against the TW10722 colonization factors CS5 and CS6, as
well as against the E. coli mucinase YghJ. Our results indicate that a human challenge model
based on a 1×1010 CFU dose of strain TW10722 will be safe and efficient to use in a trial estimat-
ing the protective efficacy of ST-based vaccine candidates for diarrhea among LMIC children
and in travelers. The model should also be suitable for evaluating the protective efficacy of vac-
cine candidates that target CS5 and CS6. In addition, since strain TW10722 does not produce
LT, the model may be useful for evaluating the effects of LT-based adjuvants, such as dmLT.
ETEC strain TW11681, which expresses colonization factor antigen I (CFA/I) and CS21, is
the only other STh-only ETEC strain that has been used in human volunteer studies [18]. Both
strains TW11681 and TW10722 belong to epidemiologically relevant ETEC families that are
commonly associated with diarrhea among LMIC children [20, 21]. When given to volunteers
in doses between 1×106 and 1×108 CFU, which normally give relatively high attack risks for
strains that produce both STh and LT [31], both these strains rarely elicited diarrhea. Within
the groups receiving the highest doses (1×108, 1×109 or 1×1010 CFU), the clinical presentation
typically ranged from no symptoms, to severe diarrhea with additional symptoms such as
abdominal cramping, mild fever and/or vomiting. This variation in disease severity, from mild
to severe, has earlier been pointed out to be a characteristic feature of challenge strains produc-
ing ST, either alone or in combination with LT [31]. Some data also suggest that the number of
guanylate cyclase C (GC-C) receptors in human intestinal membranes decreases with increas-
ing age [32], thus being lower in adults than in infants, which can help explain why some adult
volunteers develop no or very mild symptoms to ST-only ETEC infection. Another potential
explanation for the variation in symptoms we observed is that some volunteers could lack
receptors the TW10722 strain needs to properly colonize the small intestine. Although varia-
tion in these receptors has not yet been seen in humans, it is recognized as an important source
of variation in symptoms among ETEC-infected piglets [33, 34]. Finally, the early administra-
tion of antibiotic treatment to three volunteers with severe diarrhea in our current study may
also have contributed to lowering overall disease severity scores by reducing the total diarrheal
stool output.
Following the volunteers’ ingestion of TW10722, we measured immune responses targeting
both CS5 and CS6, confirming that both these colonization factors were expressed by the bac-
teria during the infection. Our study design also allowed a long follow-up of immune
responses, and to our knowledge we are the first to describe antigen-specific CD4+ T cell
responses as late as 2 years after dose ingestion, although it must be noted that the 2-year mea-
surements were based on cell culturing with a separate stock of purified protein, making
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interpretation somewhat difficult. CS5 stimulation resulted in strong antigen-specific activa-
tion of CD4+ T cells in peripheral blood, which demonstrated the strong antigenic properties
of this fimbrial colonization factor. We also observed a prominent increase in serum IgG and
IgA targeting CS5, and the response showed remarkable longevity, with some individuals still
having elevated antibody levels 2 years after dose ingestion. However, close to all volunteers in
this subgroup had been traveling in ETEC endemic countries within this 2-year period, so we
cannot rule out the possibility that some of the long-term elevated antibody responses were
boosted following more recent enteric infections. The E. coli mucinase YghJ also elicited strong
immune responses, with the anti-YghJ IgA antibody response appearing to be more prominent
than the IgG response, similar to what we observed in the sera from the volunteers experimen-
tally infected with the TW11681 strain [18]. However, being highly conserved across different
E. coli strains [25], it is likely that many of the volunteers have been pre-exposed to YghJ, and
that the rapid increase in anti-YghJ IgA and IgG represents a recall response. Interestingly,
multiple regression analysis showed that development of diarrhea, but not the TW10722 dose
size, was significantly associated with increased immune responses. However, the number of
volunteers (n = 21) is too small to draw any definitive conclusions.
CS6 is characteristically expressed by ST-positive strains (with or without LT), and it is usu-
ally present alone or with CS4 or CS5 [35]. In contrast to most other ETEC colonization fac-
tors, CS6 has a non-fimbrial morphology, and its exact function is not yet fully understood,
although CS6 has been shown to mediate bacterial adherence to enterocytes [27, 36]. Here, we
have provided the first report on CS6-specific immune responses following experimental
infection with an STh-only ETEC strain. We found that the mean proportion of CS6-specific
CD4+ T cells was significantly increased both 10 and 28 days after ingestion of TW10722,
while the increases in anti-CS6 serum antibody levels were generally small and more variable.
This is in agreement with results from safety and immunogenicity trials of the oral inactivated
ETVAX vaccine candidate showing that only a few Swedish vaccinees (3–19%) developed
a� 2-fold increase in plasma anti-CS6 antibody levels after vaccination [37]. Similar low fre-
quencies of CS6 seroconversion have also been observed in adult volunteers after ingesting the
oral live-attenuated vaccine candidate ACE527 [38] and the LT-ST-CS6-expressing challenge
strain B7A [39]. The absence of immunological priming in ETEC-naïve subjects has been sug-
gested as an explanation to these weak responses [6]. This may also help explain the variable
anti-CS6 serum antibody response observed in our Norwegian, presumably relatively ETEC-
naïve, volunteers, with only 5 (24%) and 2 (10%) of them developing a� 2-fold increase in
serum anti-CS6 IgG and IgA, respectively.
Conclusions
We here present a safe STh-only ETEC human challenge model based on the epidemiologi-
cally relevant strain TW10722 expressing the colonization factors CS5 and CS6. The strain is
safe to administer to healthy volunteers, and yielded an attack risk for moderate or severe diar-
rhea of 67% and an overall diarrheal attack risk of 78% when given in doses of 1×1010 CFU.
These estimates are based on results from experimental infection of 9 volunteers, and they will
improve when the model is used in vaccine challenge studies. The challenge model strain also
induced strong antibody responses in serum as well as CD4+ T cell responses in peripheral
blood targeting both CS5, CS6 and YghJ, some of which showed remarkable longevity with sig-
nificantly increased levels 1 year after dose ingestion. In conclusion, strain TW10722 would be
suitable for use in Phase 2B vaccine challenge trials for evaluating the efficacy of ST-based vac-
cines for ETEC diarrhea.
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